

Claims:

1. ~~A method of treating or preventing an age-related disease/condition, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject, wherein the age-related disease/condition is selected from: frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related non-alcoholic steatohepatitis (NASH), age-related cardiovascular disease, age-related hypertension, age-related renal disease and age-related skin disease.~~

Claim 12. An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in a method of treating or preventing an age-related disease/condition ~~is~~ selected from: age-related inflammation, frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related cardiovascular disease, age-related hypertension, age-related renal disease and age-related skin disease.

Claim 23. Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing an age-related disease/condition selected from: age-related inflammation, frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related non-alcoholic steatohepatitis (NASH), age-related cardiovascular disease, age-related hypertension, age-related renal disease and age-related skin disease.

Claim 34. An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in a method of treating or preventing frailty.

Claim 45. Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing frailty.

6. ~~A method of treating or preventing frailty, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject.~~

Claim 57. An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in a method of treating or preventing an age-related change in body composition.

Claim 68. Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing an age-related change in body composition.

~~9. A method of treating or preventing an age-related change in body composition, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11) mediated signalling to a subject.~~

Claim 740. An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in a method of increasing the healthspan of a subject.

Claim 844. Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of increasing the healthspan of a subject.

~~12. A method of increasing the healthspan of a subject, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11) mediated signalling to the subject.~~

Claim 943. The agent for use according to any one of claims 1, 34, 5 or 7-or-10, or the use according to any one of claims claim 2, 45, 6 or 8-or-11, or the method according to any one of claims 3, 6, 9 or 12, wherein the agent is selected from the group consisting of: an antibody or an antigen-binding fragment thereof, a polypeptide, a peptide, a nucleic acid, an oligonucleotide, an aptamer or a small molecule.

Claim 1044. The agent for use, or the use or the method according to any one of claims 1 to 943, wherein the agent is an agent capable of preventing or reducing the binding of interleukin 11 (IL-11) to a receptor for interleukin 11 (IL-11R).

Claim 1145. The agent for use, or the use or the method according to any one of claims 1 to 1044, wherein the agent is capable of binding to interleukin 11 (IL-11) or a receptor for interleukin 11 (IL-11R).

Claim 1246. The agent for use, or the use or the method according to any one of claims 1 to 1145, wherein the agent is an antibody or an antigen-binding fragment thereof.

Claim 1347. The agent for use, or the use or the method according to any one of claims 1 to 1246, wherein the agent is an anti-IL-11 antibody antagonist of IL-11-mediated signalling, or an antigen-binding fragment thereof.

Claim 1448. The agent for use, or the use or the method according to any one of claims 1 to 1246, wherein the agent is an anti-IL-11R α antibody antagonist of IL-11-mediated signalling, or an antigen-binding fragment thereof.

Claim 1549. The agent for use, or the use ~~or the method~~ according to any one of claims 1 to 1145, wherein the agent is a decoy receptor for IL-11.

Claim 1620. The agent for use, or the use ~~or the method~~ according to any one of claims 1 to 1145, wherein the agent is a competitive inhibitor of IL-11.

Claim 1724. The agent for use, or the use ~~or the method~~ according to any one of claims 1 to 943, wherein the agent is capable of preventing or reducing the expression of interleukin 11 (IL-11) or a receptor for interleukin 11 (IL-11R).

Claim 1822. The agent for use, or the use ~~or the method~~ according to claim 1724, wherein the agent is an antisense oligonucleotide capable of preventing or reducing the expression of IL-11.

Claim 1923. The agent for use, or the use ~~or the method~~ according to claim 1724, wherein the agent is an antisense oligonucleotide capable of preventing or reducing the expression of IL-11R α .

Claim 2024. The agent for use, or the use ~~or the method~~ according to any one of claims 1 to 1923, wherein the method comprises administering the agent to a subject in which expression of interleukin 11 (IL-11) or a receptor for IL-11 (IL-11R) is upregulated.